Erratum: Evaluation of galcanezumab for the prevention of episodic migraine: The EVOLVE-1 randomized clinical trial (JAMA Neurology (2018) 75: 9 (1080-1088) DOI: 10.1001/jamaneurol.2018.1212)

V. L. Stauffer, D. W. Dodick, Q. Zhang, J. N. Carter, J. Ailani, R. R. Conley

Research output: Contribution to journalComment/debate

1 Citation (Scopus)

Abstract

Error in Table: In the Original Investigation titled "Evaluation of Galcanezumab for the Prevention of Episodic Migraine:TheEVOLVE-1RandomizedClinicalTrial,"1 published onlineMay29,2018, therewas anerror inTable 1. In the 14th rowof the table, "Patients with acute medicationoveruse," thenumberandpercentagevalues should read "87 (20.2)" for the Placebo column; "39 (18.3)" for the Galcanezumab, 120 mg, column; and "42 (19.8)" for the Galcanezumab, 240mg, column. This article was corrected online.

Original languageEnglish (US)
Number of pages1
JournalJAMA neurology
Volume76
Issue number7
DOIs
StatePublished - Jul 2019

Fingerprint

Neurology
Migraine Disorders
Randomized Controlled Trials
Placebos

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Erratum : Evaluation of galcanezumab for the prevention of episodic migraine: The EVOLVE-1 randomized clinical trial (JAMA Neurology (2018) 75: 9 (1080-1088) DOI: 10.1001/jamaneurol.2018.1212). / Stauffer, V. L.; Dodick, D. W.; Zhang, Q.; Carter, J. N.; Ailani, J.; Conley, R. R.

In: JAMA neurology, Vol. 76, No. 7, 07.2019.

Research output: Contribution to journalComment/debate

@article{e875fa3a2ee94e04b75aca6c57dabce9,
title = "Erratum: Evaluation of galcanezumab for the prevention of episodic migraine: The EVOLVE-1 randomized clinical trial (JAMA Neurology (2018) 75: 9 (1080-1088) DOI: 10.1001/jamaneurol.2018.1212)",
abstract = "Error in Table: In the Original Investigation titled {"}Evaluation of Galcanezumab for the Prevention of Episodic Migraine:TheEVOLVE-1RandomizedClinicalTrial,{"}1 published onlineMay29,2018, therewas anerror inTable 1. In the 14th rowof the table, {"}Patients with acute medicationoveruse,{"} thenumberandpercentagevalues should read {"}87 (20.2){"} for the Placebo column; {"}39 (18.3){"} for the Galcanezumab, 120 mg, column; and {"}42 (19.8){"} for the Galcanezumab, 240mg, column. This article was corrected online.",
author = "Stauffer, {V. L.} and Dodick, {D. W.} and Q. Zhang and Carter, {J. N.} and J. Ailani and Conley, {R. R.}",
year = "2019",
month = "7",
doi = "10.1001/jamaneurol.2019.1177",
language = "English (US)",
volume = "76",
journal = "JAMA Neurology",
issn = "2168-6149",
publisher = "American Medical Association",
number = "7",

}

TY - JOUR

T1 - Erratum

T2 - Evaluation of galcanezumab for the prevention of episodic migraine: The EVOLVE-1 randomized clinical trial (JAMA Neurology (2018) 75: 9 (1080-1088) DOI: 10.1001/jamaneurol.2018.1212)

AU - Stauffer, V. L.

AU - Dodick, D. W.

AU - Zhang, Q.

AU - Carter, J. N.

AU - Ailani, J.

AU - Conley, R. R.

PY - 2019/7

Y1 - 2019/7

N2 - Error in Table: In the Original Investigation titled "Evaluation of Galcanezumab for the Prevention of Episodic Migraine:TheEVOLVE-1RandomizedClinicalTrial,"1 published onlineMay29,2018, therewas anerror inTable 1. In the 14th rowof the table, "Patients with acute medicationoveruse," thenumberandpercentagevalues should read "87 (20.2)" for the Placebo column; "39 (18.3)" for the Galcanezumab, 120 mg, column; and "42 (19.8)" for the Galcanezumab, 240mg, column. This article was corrected online.

AB - Error in Table: In the Original Investigation titled "Evaluation of Galcanezumab for the Prevention of Episodic Migraine:TheEVOLVE-1RandomizedClinicalTrial,"1 published onlineMay29,2018, therewas anerror inTable 1. In the 14th rowof the table, "Patients with acute medicationoveruse," thenumberandpercentagevalues should read "87 (20.2)" for the Placebo column; "39 (18.3)" for the Galcanezumab, 120 mg, column; and "42 (19.8)" for the Galcanezumab, 240mg, column. This article was corrected online.

UR - http://www.scopus.com/inward/record.url?scp=85066752408&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066752408&partnerID=8YFLogxK

U2 - 10.1001/jamaneurol.2019.1177

DO - 10.1001/jamaneurol.2019.1177

M3 - Comment/debate

C2 - 31135817

AN - SCOPUS:85066752408

VL - 76

JO - JAMA Neurology

JF - JAMA Neurology

SN - 2168-6149

IS - 7

ER -